Assessment of Grazax® Treatment Compliance

A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).

Inclusion Criteria:

• Grass pollen induced rhinoconjunctivitis
• Males and females, 18-65 years of age
• Positive skin prick test

Exclusion Criteria:

• Previous treatment with grass pollen allergen